What: online webinar
When: 4pm BST, 1 July 2020
Brexit, the United Kingdom’s departure from the European Union, is fundamentally affecting all areas of business, in the UK, the EU and beyond.
The pharmaceutical industry – that operates heavily regulated and internationally integrated supply chains – is particularly impacted in areas such as marketing authorisations, artwork, labelling and medicines supply flows, including testing and batch release and – as from 2019 – serialisation.
In the continuing absence of an agreement between the EU and the UK on the future relationship, many areas of uncertainty and many questions remain.
One area in particular gives rise to many questions: The future arrangements with regards to the EU-FMD safety features obligations and the participation in the European Medicines Verification System and processes that have been in operation since 9th February 2019: What system(s), if any will, manufacturers need to connect to from 2021 onwards for the UK? What will be the obligations regarding EU-FMD and serialised packs for the UK market from 1st January 2020? How does this impact UK packs shared with other markets such as Ireland, Malta and Cyprus?
Join our Webinar on 1st July as we speak to Jerome Bertin, General Manager at SecurMed UK, the UK NMVO, and find out what the current status is, what areas are clear, what areas are still uncertain and get expert advice on how to deal with these uncertainties and ensure that when Brexit happens, you remain in control.
How does Brexit impact pharmaceutical manufacturers supplying the EU and the UK: